Drug name
Last update: Aug 2026PGT-121 (mAb)
Developer(s)
Drug information
PGT-121
Not provided
Biotherapeutic
bNAb targeting gp120 on HIV-1 virus envelope
PGT-121 is a broadly neutralizing monoclonal antibody (bnMAb) that targets the V3-glycan epitope of the HIV-1 gp120 envelope glycoprotein. PGT122, a structurally related antibody, interacts with the gp120 outer domain at a more vertical angle relative to the apex of the viral envelope spike. The estimated serum half-life of PGT121 ranges from approximately 14 to 22 days. Following antigen binding, the PGT-121-HIV complex exhibits a sink effect, leading to rapid systemic clearance. In a phase 1 clinical trial, no treatment-related adverse events were reported; however, immune-related grade 3 adverse events were observed.
Not approved yet.
Not approved yet.
Therapeutic area(s)
- HIV
- Treatment
Administration route
Intravenous, Subcutaneous
Associated long-acting platforms
Solution
Use of drug
- Administered by a community health worker
- Administered by a nurse
- Administered by a specialty health worker
- Other/Variable/Unknown : Once every 12 weeks
Dosage
3mg/kg; 10 mg/kg and 30 mg/kg (under investigation)
30 mg/kg
PGT-121 3 mg/kg given once every 12 weeks PGT-121 10 mg/kg given once every 12 weeks PGT-121 30 mg/kg given once every 12 weeks
Not provided
Not provided
Associated compounds, formulations and regimens
Not provided
Associated technologies
Not provided
Additional information
Developer(s)
Beth Israel Deaconess Medical Center
The Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center, led by Dr. Dan Barouch, focuses on developing vaccines against infectious diseases, including HIV and COVID-19. It comprises primary and affiliate faculty dedicated to virology, vaccinology, and related disciplines. Research from the Barouch Laboratory within this center is pioneering HIV eradication.
IAVI
The International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center focuses on advancing HIV vaccine research by developing broadly neutralizing antibodies (bnAbs).
Drug structure
Scale-up and manufacturing prospects
Not provided
Lyophilizers, Mixers and Granulators, Ampoule/Vial Filling Machines, Sealing Machines
Manufacturing Process include: 1. Substitution of Amino Acid Residues: Heavy Chain (VH)/Light Chain (VL) 2. Mammalian cell expression 3. Glycoengineering to enhance Fc-effector function (e.g., afucosylation) 4. Formulation optimization: Excipients improve stability and solubility 5. Sequential vaccination: Elicits PGT-121-like bnAbs in animal models
1. HPLC 2. Mass Spectrometry 3. Spectrometers 4. pH meter 5. Yeast Surface Display 6. FACS (Fluorescence-Activated Cell Sorting) 7. Deep Sequencing
Excipients & delivery device(s)
Not provided
Not provided
Not provided
No delivery device
Safety, Efficacy and Evidence Summary
Not provided
Not provided
Not provided
Not provided
Antibody therapies for human immunodeficiency virus (hiv)
Featured are PGT121 variant antibodies or fragments thereof, which can be administered, e.g., as antibody therapies for treating human immunodeficiency virus (HIV) infection. In particular, featured are methods of treating subjects infected with HIV and/or blocking HIV infections in subjects at risk of HIV transmission using the PGT121 variant antibodies or fragments thereof.
WO2019226829A1
Not provided
Beth Israel Deaconess Medical Center, Inc.
Not provided
November 28, 2039
Active